EMA accepts marketing authorisation application for daprodustat to treat anaemia of chronic kidney disease – GSK
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the… read more.